Mannkind
MannKind develops inhaled endocrine & lung therapies, flagship Afrezza insulin and Tyvaso DPI PH, expanding pipeline with Phase‑3 MNKD‑101 (clofazimine) and early‑stage MNKD‑201 (nintedanib) while partnering with United Therapeutics, Thirona, and global distributors.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 403
- HQ: Danbury
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.